Unique ID issued by UMIN | UMIN000045270 |
---|---|
Receipt number | R000051203 |
Scientific Title | Comparison of the effect on glycemic control between oral semaglutide and DPP-4 inhibitors in patients with type 2 diabetes -prospective randomized controlled trial- |
Date of disclosure of the study information | 2021/08/26 |
Last modified on | 2024/08/29 10:44:14 |
Study for the effects of oral semaglutide on glycemic control in patients with type 2 diabetes
Oral semaglutide study
Comparison of the effect on glycemic control between oral semaglutide and DPP-4 inhibitors in patients with type 2 diabetes -prospective randomized controlled trial-
Oral semaglutide study
Japan |
Type 2 diabetes
Medicine in general | Endocrinology and Metabolism |
Others
NO
To assess the effects of switching from DPP-4 inhibitors to oral semaglutide on glycemic control in patients with type 2 diabetes
Efficacy
Exploratory
Pragmatic
Phase IV
The change in HbA1c from baseline at 24 weeks
1) The change in the other blood and urinary tests
2) The change in weight, abdominal circumference, blood pressure and pulse
3) Adverse effects
4) The factors associated with improvement of HbA1c and secondary endpoints
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
YES
Central registration
2
Treatment
Medicine |
Switch from DPP-4 inhibitors to oral semaglutide
Continue DPP-4 inhibitors
20 | years-old | <= |
90 | years-old | > |
Male and Female
1) HbA1c 7.0-10.0%
2) BMI >= 18.5 kg/m2
3) patients who were treated with DPP-4 inhibitors at least for 12 weeks before enrollment without discontinuation for more than 1 week
4) written informed consent
1) patients with type 2 diabetes who were treated with any GLP-1 receptor agonist
2) history of anaphylaxis of semaglutide
3) unstable retinopathy
4) severe hepatic dysfunction or renal dysfunction
5) severe ketosis, diabetic coma
6) severe infection, surgery, serious trauma
7) pregnancy
8) patients who are inadequate to enter this study due to the other reasons by physician's judgments
172
1st name | Hiroshi |
Middle name | |
Last name | Nomoto |
Hokkaido University Hospital
Department of Diabetes and Endocrinology
060-0838
N15W7, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan
011-706-5915
hnomoto@med.hokudai.ac.jp
1st name | Hiroshi |
Middle name | |
Last name | Nomoto |
Hokkaido University Hospital
Department of Diabetes and Endocrinology
060-0838
N15W7, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan
011-706-5915
hmiyoshi@med.hokudai.ac.jp
Hokkaido University Hospital
None
Self funding
Hokkaido University Certified Review Board
N14W5, Kita-ku, Sapporo, Hokkaido, 060-8648, Japan
011-706-7934
recjimu@huhp.hokudai.ac.jp
YES
jRCT1011210032
Japan Registry of Clinical Trials (jRCT)
020-013
Hokkaido University Certified Review Board
2021 | Year | 08 | Month | 26 | Day |
Published
174
In total, 174 eligible participants were enrolled; 17 dropped out of the study. Improvement in HbA1c at week 24 was significantly greater when switching to semaglutide compared with DPP-4i continuation . Body weight, lipid profiles and liver enzymes were significantly improved in the semaglutide group than in the DPP-4i continuation group.
2024 | Year | 08 | Month | 29 | Day |
2023 | Year | 12 | Month | 11 | Day |
Completed
2021 | Year | 06 | Month | 16 | Day |
2021 | Year | 07 | Month | 05 | Day |
2021 | Year | 08 | Month | 26 | Day |
2024 | Year | 08 | Month | 31 | Day |
2021 | Year | 08 | Month | 26 | Day |
2024 | Year | 08 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051203